http://www.twitter.comTwitter is a service for friends, family, and co-workers to communicate and stay connected through the exchange of quick, frequent answers to one simple question: What are you doing?
View Older Stories
-
Alzheimer's Disease Diagnostics & Therapeutics Market Driven by Use of Biomarkers and Advancing R&D Activities
-
Acute Myeloid Leukemia is on the Rise as Biotechs Race to Develop Groundbreaking Therapies
-
Biosense Webster Presents Late-Breaking Data from admIRE Clinical Trial at the Heart Rhythm Society Annual Meeting
-
Biosense Webster Launches New Version of CARTO™ 3 Electro-Anatomical Mapping System
-
Biosense Webster Submits Application to U.S. FDA Seeking Approval of the VARIPULSE™ Platform for the Treatment of Paroxysmal Atrial Fibrillation
-
Artelo Biosciences (ARTL) Picked as a Finalist in Johnson & Johnson’s (JNJ) Innovation Challenge
-
Artelo Biosciences Selected as a Finalist in Johnson & Johnson’s Innovation Challenge
-
Biosense Webster Presents Late-Breaking Data from inspIRE and admIRE Clinical Trials at AF Symposium
-
Genmab A/S (GMAB) Announces Decision in Arbitration Appeal under License Agreement with Janssen
-
Biosense Webster Announces Regulatory Approval of VARIPULSE™ Pulsed Field Ablation (PFA) Platform in Japan
-
Johnson & Johnson MedTech (JNJ) Acquires Laminar, Inc. for $400 Million Plus Milestone Payments
-
Johnson & Johnson MedTech Acquires Laminar, Inc.
-
New Biosense Webster QDOT MICRO™ Catheter Data Demonstrate Very High-Power, Short-Duration Ablations Improved Quality of Life and Reduced Healthcare Utilization for AFib Patients
-
Press Release Biocartis Group NV: Disclosure of transparency notification
-
Biosense Webster Receives FDA Approval for Multiple Atrial Fibrillation Ablation Products to be Used in a Workflow Without Fluoroscopy
-
Biosense Webster Launches the OPTRELL™ Mapping Catheter with TRUEref™ Technology for Mapping of Complex Cardiac Arrhythmias
-
Galapagos appoints Thad Huston as Chief Financial Officer and Chief Operating Officer
-
Healthcare Week boon for medical industry
-
Asia Summit on Global Health gathers 90+ global elites
-
New Data Published on Biosense Webster QDOT MICRO™ Catheter - the Latest Advancement in Focal RF Ablation for Treating AFib
-
International Healthcare Week returns to showcase Hong Kong's strengths in healthcare innovation and investment
-
Virtual Incision Expands Leadership Team as it Prepares for New Market Growth
-
AtlantiCare First in Northeast to Deploy Optellum AI Alongside Robotics for Early Lung Cancer Diagnosis and Treatment
-
First Look at Data on Biosense Webster's Investigational Pulsed Field Ablation Platform Presented at AF Symposium 2023
-
Late Breaking Data on Pulmonary Vein Isolation with HELIOSTAR™ Balloon Ablation Catheter Presented at AF Symposium 2023
-
Biosense Webster, Inc. to Highlight Latest Innovations at AF Symposium 2023 Showcasing Breadth of Cardiac Rhythm Portfolio
-
3 stock rumors being discussed on trading floors today
-
Healthcare and Medical Leaders Gather to Shape the Future of Global Health
-
Spotlight on Healthcare Collaboration and Innovation at Asia Summit on Global Health and HK International Medical and Healthcare Fair
-
Inaugural International Healthcare Week promotes Hong Kong as leading healthcare hub
-
Johnson & Johnson Vision Reveals New Data on Blue-Violet Light Filtering Technology in ACUVUE® OASYS MAX 1-DAY Contact Lenses
-
Biosense Webster Launches HELIOSTAR™ in Europe, the First Radiofrequency Balloon Ablation Catheter, Enabling Physicians to Perform More Efficient Cardiac Ablations
-
Johnson & Johnson Vision Expands Access to Myopia Management for More Patients with Abiliti™ Overnight Lenses
-
Johnson & Johnson Vision Introduces All Purpose EDOF, TECNIS Symfony OptiBlue IOL, the Latest PC-IOL Powered by InteliLight Technology
-
Johnson & Johnson Vision Launches New Contact Lens Innovation to Help Meet the Needs of Digitally Intense Lifestyles: ACUVUE® OASYS MAX 1-Day
-
Biosense Webster Launches the OCTARAY™ Mapping Catheter with TRUEref™ Technology
-
Johnson & Johnson Opens First Satellite Center for Global Health Discovery in Asia Pacific at Duke-NUS to Advance Dengue Research
-
Johnson & Johnson (JNJ) Announces FDA Clearance of ACUVUE OASYS MAX 1-Day
-
Johnson & Johnson Vision on Track for Multinational Launch of New Contact Lens Innovation: ACUVUE® OASYS MAX 1-Day
-
Johnson & Johnson Vision Named a Winner of Fast Company's 2022 World Changing Ideas Awards for ACUVUE® Theravision™ with Ketotifen
-
Johnson & Johnson Launches Next Satellite Center for Global Health Discovery at Holistic Drug Discovery and Development Centre, University of Cape Town, Focused on Antimicrobial Resistance (AMR)
-
Ventus Therapeutics Appoints Victor Lobanov, PhD, as Head of Computational Sciences
-
Johnson & Johnson (JNJ) Announces Positive CHMP Opinion Recommending CARVYKTI for Treatment of Patients with Relapsed and Refractory Multiple Myeloma
-
Johnson & Johnson (JNJ) Vision Care Receives FDA Approval for ACUVUE Theravision with Ketotifen
-
Johnson & Johnson Vision Care Receives FDA Approval for ACUVUE® Theravision™ with Ketotifen - World's First and Only Drug-Eluting Contact Lens
-
Arrowhead Pharmaceuticals Inc. (ARWR) Announces JNJ-75220795 in Development for NASH (JNJ)
-
Wall Street ends higher with boost from big tech
-
Data suggests mRNA booster dose generates stronger antibody response after J&J shot - Axios
-
Johnson & Johnson Vision Announces New Collaboration to Eliminate Inequities and Increase Representation of People of Color in the Eye Care Industry
-
Johnson & Johnson's (JNJ) Phase 2b Imbokodo HIV Vaccine Clinical Trial in Young Women in Sub-Saharan Africa Did Not Provide Sufficient Protection Against HIV

